Page last updated: 2024-10-25

clenbuterol and Chronic Disease

clenbuterol has been researched along with Chronic Disease in 14 studies

Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.

Chronic Disease: Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2).

Research Excerpts

ExcerptRelevanceReference
"Twenty-one patients with chronic bronchitis and reversible airway obstruction participated in two single-blind, cross-over, placebo-controlled studies in inhaled clenbuterol - a new bronchodilator - and salbutamol."9.05A comparison between inhaled clenbuterol and salbutamol in chronic bronchitis with reversible airway obstruction. ( Baronti, A; Grieco, A; Vibelli, C, 1980)
"Clenbuterol was well tolerated and led to a significant increase in both lean mass and the lean/fat ratio."6.73Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. ( George, I; Kamalakkannan, G; LaManca, J; Mancini, DM; Maybaum, S; McLaughlin, BT; Petrilli, CM; Shane, E, 2008)
"Twenty-one patients with chronic bronchitis and reversible airway obstruction participated in two single-blind, cross-over, placebo-controlled studies in inhaled clenbuterol - a new bronchodilator - and salbutamol."5.05A comparison between inhaled clenbuterol and salbutamol in chronic bronchitis with reversible airway obstruction. ( Baronti, A; Grieco, A; Vibelli, C, 1980)
"A new oral bronchodilator, NAB 365 (clenbuterol), at doses of 10, 20, 30 and 40 microgram, was studied in a double-blind placebo-controlled incomplete cross-over study in 10 patients suffering from chronic bronchitis who had reversible airway obstruction."5.04Dose-response study of a new oral bronchodilator, NAB 365 (clenbuterol). ( Brusasco, V; Chierichetti, S; Ramoino, R; Vibelli, C, 1978)
"Clenbuterol was well tolerated and led to a significant increase in both lean mass and the lean/fat ratio."2.73Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure. ( George, I; Kamalakkannan, G; LaManca, J; Mancini, DM; Maybaum, S; McLaughlin, BT; Petrilli, CM; Shane, E, 2008)
"Treatment with clenbuterol caused changes only in calves with subacute bronchopneumonia; in these animals it decreased the total pulmonary resistance, the viscous work per litre and the peak to peak changes in transpulmonary pressure."1.27The effects of clenbuterol hydrochloride on the pulmonary function of calves with subacute and chronic bronchopneumonia. ( Hajer, R, 1988)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19909 (64.29)18.7374
1990's2 (14.29)18.2507
2000's3 (21.43)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fujimura, M2
Kamalakkannan, G1
Petrilli, CM1
George, I1
LaManca, J1
McLaughlin, BT1
Shane, E1
Mancini, DM1
Maybaum, S1
Kawakami, Y1
Král, B1
Jirkal, J1
Eliás, J1
Ilnerová, A1
Dolezalová, K1
Tilser, P1
Baronti, A2
Grieco, A1
Vibelli, C3
Kamio, Y1
Hashimoto, T1
Matsuda, T1
Chan, TY1
Rensch, H1
Renovanz, HD1
Cummiskey, J1
Keelan, P1
Gray, P1
Cox, GA1
Griceo, A1
Brusasco, V1
Chierichetti, S1
Ramoino, R1
Dorow, P1
Su, WJ1
Perng, RP1
Hajer, R1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Clinical Investigation of the Safety and Efficacy of Clenbuterol on Motor Function in Individuals With Late-onset Pompe Disease and Receiving Enzyme Replacement Therapy[NCT01942590]Phase 1/Phase 217 participants (Actual)Interventional2013-09-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in 6 Minute Walk Test

Assess exercise tolerance in study patients; test administered by physical therapist. Subjects were asked to walk for 6 minutes, unassisted. The distance walked was recorded in meters. (NCT01942590)
Timeframe: Baseline, week 18

Interventionmeters (Mean)
Clenbuterol18.09
Placebo Comparator6.878

Change in 6 Minute Walk Test

Assess exercise tolerance in study patients; test administered by physical therapist. Subjects were asked to walk for 6 minutes, unassisted. The distance walked was recorded in meters. (NCT01942590)
Timeframe: Baseline, week 52

Interventionmeters (Mean)
Clenbuterol16.42
Placebo Comparator-18.13

Change in Forced Vital Capacity (FVC) in Pulmonary Function Testing

Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. (NCT01942590)
Timeframe: Baseline, Week 18

Interventionchange in FVC measured as % expected (Mean)
Clenbuterol1.575
Placebo Comparator2.825

Change in Forced Vital Capacity (FVC) in Pulmonary Function Testing

Forced vital capacity (FVC) is the total amount of air exhaled during the lung function test. (NCT01942590)
Timeframe: Baseline, Week 52

Interventionchange in FVC measured as % expected (Mean)
Clenbuterol-5.738
Placebo Comparator7.775

Change in Urinary Glc4 Biomarker

(NCT01942590)
Timeframe: Baseline, Week 52

Interventionmmol/mol CN (Mean)
Clenbuterol-1.1
Placebo Comparator-1.667

Change in Urinary Glc4 Biomarker

The Glc4 biomarker is measured in urine and correlates with muscle glycogen content. It is a noninvasive measurement that serves as a biomarker for Pompe disease. (NCT01942590)
Timeframe: Baseline, Week 18

Interventionmmol/mol CN (Mean)
Clenbuterol-1.733
Placebo Comparator0.0667

Number of Participants With a Change in Aspartate Aminotransferase (AST), Alanine Transaminase (ALT), and Bilirubin Representing Liver Toxicity

Liver toxicity, as defined by a >3x increase in AST or ALT from the respective baseline values and/or an increase in direct, indirect or total bilirubin of >3x the upper limit of normal (NCT01942590)
Timeframe: Any point up to week 52

Interventionparticipants (Number)
Clenbuterol0
Placebo Comparator0

Number of Participants With a Change in Creatine Kinase (CK) Reflecting Worsening of Muscle Involvement

Worsening muscle involvement, as defined by >3x increase in CK from baseline that is >2x the upper limit of normal (NCT01942590)
Timeframe: Any point up to week 52

Interventionparticipants (Number)
Clenbuterol1
Placebo Comparator0

GSGC (Gait, Stairs, Gowers, Arising From a Chair.)

The GSGC is a criterion referenced assessment designed to measure functional status and change in gross motor function over time and, in particular, to measure clinically relevant change. Consists of 4 components: Gait, Climbing Stairs, Gower's Manuever, Arising From a Chair. Lowest score 4 = normal muscle function, highest score 27 = unable to perform motor function tests. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52

,
Interventionunits on a scale (Mean)
BaselineWeek 18Week 52
Clenbuterol1715.1413.8
Placebo Comparator7.56.56.5

Late-Life Function and Disability Instrument (LLFDI)

The Late-Life Function & Disability Instrument (Late-Life FDI) is an evaluative outcome instrument for community-dwelling older adults. Highest score 240 = normal function and no disability, lowest score 0 = low levels of frequency of participating in life tasks. (NCT01942590)
Timeframe: Baseline, Week 18, Week 52

Interventionunits on a scale (Mean)
BaselineWeek 18Week 52
Clenbuterol103.75106.7112.5

Maximum Expiratory Pressure (MEP)

MEP reflects the strength of the abdominal muscles and other expiratory muscles. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52

,
Interventionpercentage of MEP (Mean)
BaselineWeek 18Week 52
Clenbuterol40.44053.9
Placebo Comparator62.883.349.2

Predicted Maximum Inspiration Pressure (MIP)

MIP is a measurement of inspiratory muscle weakness, including weakness of the diaphragm. MIP is decreased in Pompe disease and reflects weakness of respiratory muscles. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52

,
Interventionpercentage of MIP (Mean)
BaselineWeek 18Week 52
Clenbuterol56.347.468.5
Placebo Comparator96.883.8104.6

Quick Motor Function Test (QMFT)

The QMFT is a criterion referenced assessment designed to measure functional status and change in gross motor function over time and, in particular, to measure clinically relevant change. Consists of 16 motor function tests. Lowest score 0 = unable to perform motor function tests, highest score 64 = normal muscle function. (NCT01942590)
Timeframe: Baseline, Week 18, and Week 52

,
Interventionunits on a scale (Mean)
BaselineWeek 18Week 52
Clenbuterol3540.646.5
Placebo Comparator53.7554.7556.25

Reviews

3 reviews available for clenbuterol and Chronic Disease

ArticleYear
[Causes of prolonged and chronic cough].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 2008, Volume: 131, Issue:6

    Topics: Adrenergic beta-Agonists; Albuterol; Androstadienes; Asthma; Chronic Disease; Clenbuterol; Cough; Dr

2008
Food-borne clenbuterol may have potential for cardiovascular effects with chronic exposure (commentary).
    Journal of toxicology. Clinical toxicology, 2001, Volume: 39, Issue:4

    Topics: Adrenergic beta-Agonists; Animals; Chronic Disease; Clenbuterol; Food Contamination; Hemodynamics; H

2001
[Clenbuterol: review of a new broncholytic agent].
    Medizinische Monatsschrift, 1977, Volume: 31, Issue:10

    Topics: Bronchi; Chronic Disease; Clenbuterol; Ethanolamines; Humans; Lung Diseases, Obstructive

1977

Trials

6 trials available for clenbuterol and Chronic Disease

ArticleYear
Clenbuterol increases lean muscle mass but not endurance in patients with chronic heart failure.
    The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2008, Volume: 27, Issue:4

    Topics: Adrenergic beta-Agonists; Adult; Body Composition; Chronic Disease; Clenbuterol; Double-Blind Method

2008
First clinical studies on mabuterol. A summarizing report.
    Arzneimittel-Forschung, 1984, Volume: 34, Issue:11A

    Topics: Adrenergic beta-Antagonists; Adult; Asthma; Bronchodilator Agents; Cardiovascular System; Chronic Di

1984
A comparison between inhaled clenbuterol and salbutamol in chronic bronchitis with reversible airway obstruction.
    European journal of respiratory diseases, 1980, Volume: 61, Issue:3

    Topics: Aerosols; Aged; Airway Obstruction; Albuterol; Bronchitis; Chronic Disease; Clenbuterol; Clinical Tr

1980
Comparison of NAB 365 and salbutamol tablets in chronic bronchitis and asthma.
    Irish medical journal, 1978, Mar-18, Volume: 71, Issue:4

    Topics: Adult; Aged; Albuterol; Asthma; Bronchitis; Chronic Disease; Clenbuterol; Clinical Trials as Topic;

1978
Study of a new oral beta-adrenergic drug, clenbuterol, in patients with chronic bronchitis.
    European journal of clinical pharmacology, 1978, May-31, Volume: 13, Issue:3

    Topics: Aged; Bronchitis; Bronchodilator Agents; Chronic Disease; Clenbuterol; Clinical Trials as Topic; Dou

1978
Dose-response study of a new oral bronchodilator, NAB 365 (clenbuterol).
    International journal of clinical pharmacology and biopharmacy, 1978, Volume: 16, Issue:12

    Topics: Adult; Airway Resistance; Bronchitis; Chronic Disease; Clenbuterol; Clinical Trials as Topic; Dose-R

1978

Other Studies

5 other studies available for clenbuterol and Chronic Disease

ArticleYear
Spiropent in the treatment of reversible airways obstruction.
    Sbornik vedeckych praci Lekarske fakulty Karlovy univerzity v Hradci Kralove. Supplementum, 1982, Volume: 25, Issue:5

    Topics: Adult; Asthma; Bronchitis; Child; Chronic Disease; Clenbuterol; Ethanolamines; Humans

1982
Cough receptor sensitivity and bronchial responsiveness in patients with only chronic nonproductive cough: in view of effect of bronchodilator therapy.
    The Journal of asthma : official journal of the Association for the Care of Asthma, 1994, Volume: 31, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Bronchial Hyperreactivity; Bronchial Provocation Tests; Bronchodilat

1994
[Mono- and combination therapy in chronic obstructive bronchitis. The effect of a mono- and combination therapy on total resistance in patients with chronic obstructive bronchitis].
    ZFA. Zeitschrift fur Allgemeinmedizin, 1979, Feb-10, Volume: 55, Issue:4

    Topics: Airway Resistance; Bronchitis; Chronic Disease; Clenbuterol; Drug Therapy, Combination; Ethylenediam

1979
Spiropent (clenbuterol): another choice for patients with chronic reversible airways obstruction.
    Zhonghua yi xue za zhi = Chinese medical journal; Free China ed, 1991, Volume: 47, Issue:1

    Topics: Adult; Aged; Airway Obstruction; Chronic Disease; Clenbuterol; Female; Humans; Male; Middle Aged

1991
The effects of clenbuterol hydrochloride on the pulmonary function of calves with subacute and chronic bronchopneumonia.
    The Veterinary record, 1988, Oct-01, Volume: 123, Issue:14

    Topics: Animals; Bronchopneumonia; Cattle; Cattle Diseases; Chronic Disease; Clenbuterol; Ethanolamines; Res

1988